Dimethylsiloxane polymers for the effective transdermal delivery of Minoxidil in hair loss treatment.

IF 2.8 4区医学 Q2 ENGINEERING, BIOMEDICAL Biomedical Engineering Letters Pub Date : 2025-01-29 eCollection Date: 2025-03-01 DOI:10.1007/s13534-025-00460-0

Jaehoon Kim, Dokyoung Kim

{"title":"Dimethylsiloxane polymers for the effective transdermal delivery of Minoxidil in hair loss treatment.","authors":"Jaehoon Kim, Dokyoung Kim","doi":"10.1007/s13534-025-00460-0","DOIUrl":null,"url":null,"abstract":"Purpose: Hair loss affects significant social and psychological well-being issues of the person. Thus, various drugs, ingredients, and technologies are being developed to overcome it. Minoxidil (MXD) is a representative hair loss treatment drug because it suppresses the production of dihydrotestosterone and induces vasodilation. However, since MXD has various side effects when used orally, it is more desirable to use it topically. In this work, we disclosed a new polymeric formulation (MXD@CP) based on citric acid (CA) dimethylsiloxane polymer (CP) for the effective transdermal delivery of MXD.Methods: The polymer that induced ring-opening polymerization based on CA was named CA-siloxane polymer (CP). After CP synthesis, MXD was loaded onto CP to form MXD@CP. The formed MXD@CP was confirmed to have efficacy as a transdermal delivery system through various material property analyses and biotoxicity and therapeutic efficacy analyses.Results: In these results, CP stably loaded MXD up to 5%, a concentration used in clinical practice, and showed higher hair growth efficacy and hair follicle formation efficacy compared to MXD@PBS.Conclusion: In the animal study, MXD@CP showed a superior hair growth effect which suggests its potential as a next-generation hair loss treatment agent.Supplementary information: The online version contains supplementary material available at 10.1007/s13534-025-00460-0.","PeriodicalId":46898,"journal":{"name":"Biomedical Engineering Letters","volume":"15 2","pages":"437-442"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871241/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Engineering Letters","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s13534-025-00460-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Hair loss affects significant social and psychological well-being issues of the person. Thus, various drugs, ingredients, and technologies are being developed to overcome it. Minoxidil (MXD) is a representative hair loss treatment drug because it suppresses the production of dihydrotestosterone and induces vasodilation. However, since MXD has various side effects when used orally, it is more desirable to use it topically. In this work, we disclosed a new polymeric formulation (MXD@CP) based on citric acid (CA) dimethylsiloxane polymer (CP) for the effective transdermal delivery of MXD.

Methods: The polymer that induced ring-opening polymerization based on CA was named CA-siloxane polymer (CP). After CP synthesis, MXD was loaded onto CP to form MXD@CP. The formed MXD@CP was confirmed to have efficacy as a transdermal delivery system through various material property analyses and biotoxicity and therapeutic efficacy analyses.

Results: In these results, CP stably loaded MXD up to 5%, a concentration used in clinical practice, and showed higher hair growth efficacy and hair follicle formation efficacy compared to MXD@PBS.

Conclusion: In the animal study, MXD@CP showed a superior hair growth effect which suggests its potential as a next-generation hair loss treatment agent.

Supplementary information: The online version contains supplementary material available at 10.1007/s13534-025-00460-0.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于治疗脱发的米诺地尔有效经皮递送的二甲基硅氧烷聚合物。

目的：脱发会影响一个人的社会和心理健康问题。因此，人们正在开发各种药物、成分和技术来克服它。米诺地尔（MXD）是一种代表性的脱发治疗药物，因为它可以抑制双氢睾酮的产生并诱导血管舒张。然而，由于MXD在口服时有各种副作用，因此更可取的是局部使用。在这项工作中，我们公开了一种基于柠檬酸（CA）二甲基硅氧烷聚合物（CP）的新型聚合物配方（MXD@CP），用于MXD的有效透皮递送。方法：将CA诱导开环聚合的聚合物命名为CA-硅氧烷聚合物（CP）。合成CP后，将MXD加载到CP上形成MXD@CP。通过各种材料特性分析、生物毒性和治疗效果分析，证实了形成的MXD@CP作为透皮给药系统的有效性。结果：在这些结果中，CP稳定地负载了高达5%的MXD，这是临床实践中使用的浓度，并且与MXD@PBS.Conclusion相比，显示出更高的毛发生长和毛囊形成功效。在动物研究中，MXD@CP显示出优越的毛发生长效果，这表明其作为下一代脱发治疗剂的潜力。补充信息：在线版本包含补充资料，下载地址为10.1007/s13534-025-00460-0。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biomedical Engineering Letters ENGINEERING, BIOMEDICAL-

CiteScore

6.80

自引率

0.00%

发文量

期刊介绍： Biomedical Engineering Letters (BMEL) aims to present the innovative experimental science and technological development in the biomedical field as well as clinical application of new development. The article must contain original biomedical engineering content, defined as development, theoretical analysis, and evaluation/validation of a new technique. BMEL publishes the following types of papers: original articles, review articles, editorials, and letters to the editor. All the papers are reviewed in single-blind fashion.